Generali Asset Management SPA SGR Buys Shares of 10,197 IQVIA Holdings Inc. (NYSE:IQV)

Generali Asset Management SPA SGR purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, HoldingsChannel reports. The firm purchased 10,197 shares of the medical research company’s stock, valued at approximately $2,004,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Tocqueville Asset Management L.P. boosted its stake in shares of IQVIA by 6.3% in the 4th quarter. Tocqueville Asset Management L.P. now owns 26,147 shares of the medical research company’s stock worth $5,138,000 after buying an additional 1,547 shares during the last quarter. Terra Alpha Investments LLC purchased a new position in shares of IQVIA in the 4th quarter worth $1,434,000. Signaturefd LLC boosted its stake in shares of IQVIA by 13.6% in the 4th quarter. Signaturefd LLC now owns 2,894 shares of the medical research company’s stock worth $569,000 after buying an additional 346 shares during the last quarter. Cibc World Markets Corp boosted its stake in shares of IQVIA by 15.0% in the 4th quarter. Cibc World Markets Corp now owns 27,629 shares of the medical research company’s stock worth $5,429,000 after buying an additional 3,604 shares during the last quarter. Finally, Nicholas Company Inc. boosted its stake in shares of IQVIA by 0.4% in the 4th quarter. Nicholas Company Inc. now owns 84,404 shares of the medical research company’s stock worth $16,586,000 after buying an additional 303 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IQV. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Trading Down 0.9 %

Shares of IQVIA stock opened at $186.80 on Thursday. The firm has a market cap of $32.93 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.99 and a beta of 1.50. The business has a 50-day moving average price of $195.71 and a 200-day moving average price of $209.36. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.29.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.